Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives.
CD1a
RCC
dendritic cells
exceptional responder
nivolumab
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
01
2020
accepted:
07
07
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Immunotherapy may result in long-lasting exceptional clinical responses, the molecular background of which is inadequately understood. Here, we present the case of a 63-year-old patient with a past medical history of renal cancer who relapsed many years later. Several treatment lines were administered prior to immunotherapy, which was administered in the ninth line, achieving complete remission which had lasted for more than 3 years. Genomic alterations, tumor mutational burden (TMB), and microsatellite instability as well as PD-L1, MLH1, MSH2, MSH6, PMS2, CD3, CD8, CD20, CD138, CD1a, and FoxP3 expression were assessed in primary and metastatic tumors. Primary and metastatic tumors were microsatellite stable with high TMB, while somatic mutations in
Identifiants
pubmed: 32849917
doi: 10.1177/1758835920946152
pii: 10.1177_1758835920946152
pmc: PMC7425249
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1758835920946152Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Cancer Cell Int. 2018 Oct 17;18:159
pubmed: 30349421
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Br J Cancer. 2018 May;118(9):1238-1242
pubmed: 29674707
Urol Int. 2001;66(2):78-83
pubmed: 11223748
Curr Opin Oncol. 2016 Mar;28(2):122-9
pubmed: 26756384
Transl Oncol. 2018 Oct;11(5):1171-1187
pubmed: 30059832
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Oncotarget. 2017 May 31;8(35):59901-59914
pubmed: 28938692
J Med Genet. 1995 Dec;32(12):942-5
pubmed: 8825920
Am Soc Clin Oncol Educ Book. 2018 May 23;38:787-794
pubmed: 30231384
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
J Cutan Pathol. 2018 May;45(5):337-347
pubmed: 29419888
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9
pubmed: 12826609
Clin Cancer Res. 2018 Nov 15;24(22):5710-5723
pubmed: 29764856
Ann Oncol. 2019 Mar 1;30(3):385-396
pubmed: 30657859
Crit Rev Oncol Hematol. 2019 Mar;135:47-58
pubmed: 30819446
J Clin Oncol. 2014 Jun 20;32(18):1968-76
pubmed: 24821879
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
J Cancer. 2014 Jan 24;5(3):166-72
pubmed: 24563671
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
J Urol. 2001 Jul;166(1):63-7
pubmed: 11435824
Oncotarget. 2017 Oct 19;8(60):102361-102370
pubmed: 29254251
J Med Genet. 2001 Apr;38(4):253-7
pubmed: 11370630